Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-month Real Life Study of IBD Patients Under Stable Steroid Free Clinical and Biological Remission Switched From Adalimumab Originator Humira® to One of Its Biosimilar: Amgevita®,Hulio®,Hyrimoz® or Imraldi®.

NCT04422171 is registered in ClinicalTrials.gov with University Hospital, Grenoble as lead sponsor.

NCT NCT04422171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04422171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-month Real Life Study of IBD Patients Under Stable Steroid Free Clinical and Biological Remission Switched From Adalimumab Originator Humira® to One of Its Biosimilar: Amgevita®,Hulio®,Hyrimoz® or Imraldi®.
Lead sponsor
University Hospital, Grenoble
Phase
Observational
Overall status
Unknown status
Start date
June 19, 2020
Completion date
January 31, 2023
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ibd patients, originator treatment, biosimilar, switch back